Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8097683rdf:typepubmed:Citationlld:pubmed
pubmed-article:8097683lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C0028351lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:8097683lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:8097683pubmed:issue4lld:pubmed
pubmed-article:8097683pubmed:dateCreated1993-6-1lld:pubmed
pubmed-article:8097683pubmed:abstractText1. To investigate the effects of acute beta 1-adrenoceptor blockade on sympathetic nervous activity, cardiac and whole-body noradrenaline kinetics were determined during intravenous infusions of saline placebo and of metoprolol (10-15 mg plus 150 micrograms min-1 kg-1) in 10 patients undergoing diagnostic cardiac catheterization, in whom beta-adrenoceptor antagonists had been discontinued for 7 days. 2. Coronary haemodynamics were measured in these 10 patients plus two others. Compared with saline placebo, metoprolol administration was associated with decreases in heart rate (68 +/- 2 to 59 +/- 3 beats/min, P < 0.001) and coronary sinus blood flow (86 +/- 8 to 68 +/- 6 ml/min, P < 0.001) and an increase in calculated coronary vascular resistance (1.42 +/- 0.19 to 1.75 +/- 0.22 mmHg min ml-1, P < 0.001). Arterial and femoral venous noradrenaline concentrations, whole-body noradrenaline clearance and whole-body noradrenaline spillover to arterial plasma did not change. In contrast, cardiac noradrenaline spillover (33.7 +/- 5.1 to 20.2 +/- 4.3 pmol/min, P < 0.05) and cardiac noradrenaline clearance (31 +/- 3 to 23 +/- 3 ml/min, P < 0.001) were significantly decreased during metoprolol administration. 3. These results may be explained by inhibition of pre-junctional facilitatory beta-adrenoceptors, which we hypothesize may be predominantly of the beta 1-subtype in the heart and of the beta 2-subtype in the periphery.lld:pubmed
pubmed-article:8097683pubmed:languageenglld:pubmed
pubmed-article:8097683pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8097683pubmed:citationSubsetIMlld:pubmed
pubmed-article:8097683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8097683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8097683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8097683pubmed:statusMEDLINElld:pubmed
pubmed-article:8097683pubmed:monthAprlld:pubmed
pubmed-article:8097683pubmed:issn0143-5221lld:pubmed
pubmed-article:8097683pubmed:authorpubmed-author:ForfarJ CJClld:pubmed
pubmed-article:8097683pubmed:authorpubmed-author:McCanceA JAJlld:pubmed
pubmed-article:8097683pubmed:issnTypePrintlld:pubmed
pubmed-article:8097683pubmed:volume84lld:pubmed
pubmed-article:8097683pubmed:ownerNLMlld:pubmed
pubmed-article:8097683pubmed:authorsCompleteYlld:pubmed
pubmed-article:8097683pubmed:pagination413-7lld:pubmed
pubmed-article:8097683pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:meshHeadingpubmed-meshheading:8097683-...lld:pubmed
pubmed-article:8097683pubmed:year1993lld:pubmed
pubmed-article:8097683pubmed:articleTitleNoradrenaline kinetics and coronary haemodynamics during acute beta 1-adrenoceptor blockade in man.lld:pubmed
pubmed-article:8097683pubmed:affiliationDepartment of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, U.K.lld:pubmed
pubmed-article:8097683pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8097683pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8097683pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8097683pubmed:publicationTypeControlled Clinical Triallld:pubmed